Advancedcell biology
Nucleolar Stress: The Ribosome Biogenesis Checkpoint
Overview
The nucleolus monitors ribosome production. Disrupted ribosome biogenesis triggers 'nucleolar stress': free ribosomal proteins bind MDM2, stabilizing p53 and arresting the cell cycle — a quality-control checkpoint with roles in cancer and ribosomopathies.
Learning objectives
- Explain the nucleolar stress pathway
- Describe the RPL5/RPL11–MDM2–p53 axis
- Give examples of ribosomopathies
- Discuss therapeutic implications
The nucleolus as a sensor
Ribosome biogenesis consumes enormous resources. The nucleolus senses disruptions — nutrient starvation, DNA damage, oncogene activation — and converts them into p53 signaling.
Failed ribosome production → free ribosomal proteins → p53 activation → arrest.
The RPL5/RPL11–MDM2 axis
Normally, ribosomal proteins RPL5 and RPL11 assemble into ribosomes. When biogenesis stalls, they accumulate free, bind the ubiquitin ligase MDM2, and block p53 degradation — p53 rises and halts the cycle.
RPL5/RPL11 + 5S rRNA form a complex that sequesters MDM2 — memorize this trio.
Ribosomopathies
Diamond-Blackfan anemia (ribosomal protein haploinsufficiency), Treacher Collins syndrome, Shwachman-Diamond syndrome — paradoxically, these p53-activating disorders increase cancer risk.
The Dameshek riddle: why do ribosome defects cause both bone-marrow failure AND cancer predisposition?
Cancer connections
Oncogenes like MYC drive ribosome biogenesis; chemotherapies (actinomycin D) trigger nucleolar stress deliberately. p53-mutant cancers evade this checkpoint.
Nucleolar stress links growth control to tumor suppression — a therapeutic lever.
Therapeutic targeting
Drugs that induce nucleolar stress (CX-5461, inhibiting Pol I) selectively kill cancer cells addicted to high ribosome output — now in clinical trials.
RNA Pol I inhibitors exploit cancer cells' ribosome addiction.
Key points
- Nucleolus monitors ribosome output
- RPL5/RPL11 block MDM2
- p53 stabilization arrests the cycle
- Ribosomopathies: DBA, Treacher Collins
- Pol I inhibitors in trials
Common misconceptions
✓ Truth: It also senses stress, sequesters proteins, and coordinates cell-cycle decisions.
✓ Truth: Their hallmark is p53-driven developmental defects and cancer predisposition, not just slow translation.
Practice questions
Q1. In nucleolar stress, p53 is stabilized because free ribosomal proteins:
- Inhibit MDM2
- Activate MDM2
- Degrade p53 directly
- Block transcription
RPL5/RPL11 binding blocks MDM2's ubiquitin ligase activity toward p53.
Q2. Diamond-Blackfan anemia results from:
- Ribosomal protein haploinsufficiency
- Hemoglobin mutation
- Iron deficiency
- Viral infection
DBA is the classic ribosomopathy — ribosomal protein mutations causing red-cell aplasia.
Q3. By what mechanism does the drug CX-5461 work?
- Inhibiting RNA polymerase I
- Blocking DNA replication
- Chelating iron
- Activating telomerase
Pol I inhibition triggers nucleolar stress, selectively killing ribosome-addicted cancer cells.
Click a question to reveal the answer and explanation.
Frequently asked questions
Outline the nucleolar stress pathway.
Disrupted rRNA synthesis or ribosome assembly leaves RPL5/RPL11/5S rRNA free; they bind MDM2, preventing p53 ubiquitination; stabilized p53 induces cell-cycle arrest or apoptosis.
What are ribosomopathies? Give two examples.
Diseases from ribosomal protein or biogenesis defects: Diamond-Blackfan anemia (red cell failure) and Treacher Collins syndrome (craniofacial defects) — both involve p53 hyperactivation.
Why target RNA Pol I in cancer therapy?
Cancer cells demand extreme ribosome output; Pol I inhibitors (CX-5461) trigger nucleolar stress selectively in these addicted cells while sparing normal ones.